KIMBERLY WACHTER: Open Payments
NPI 1851481071 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$895 in 20 payments from 8 companies in 2025. Trend: 2023 $494 · 2024 $856 · 2025 $895
Food & beverage: $895
| Company | Payments | Amount |
|---|---|---|
| Edwards Lifesciences Corporation | 7 | $541 |
| Boston Scientific Corporation | 2 | $118 |
| Actelion Pharmaceuticals US, Inc. | 3 | $69 |
| Chiesi USA, Inc. | 2 | $58 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $30 |
| Novartis Pharmaceuticals Corporation | 2 | $27 |
| SCPHARMACEUTICALS INC. | 1 | $16 |
Products named: WATCHMAN FLX, OPSUMIT, FARXIGA, JARDIANCE, KENGREAL, CLEVIPREX, LEQVIO, FUROSCIX.
Industry payments across MD — which companies pay providers there.
